Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 9/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807850 | 0.92 | ALDH1A1 (0.45) | KDM4EALDH1A1HPGDHSD17B10GRIA2 | |
| SCHEMBL4800665 | 0.88 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10GRIA2 | |
| SCHEMBL4806754 | 0.85 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10GRIA2 | |
| SCHEMBL4810196 | 0.84 | HPGD (0.52) | KDM4EALDH1A1HPGDHSD17B10GRIA2 | |
| SCHEMBL5768368 | 0.83 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10GRIA2 | |
| SCHEMBL5640361 | 0.83 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10GRIA2 | |
| SCHEMBL5643891 | 0.82 | HPGD (0.46) | KDM4EALDH1A1HPGDHSD17B10GRIA2 | |
| SCHEMBL5640743 | 0.82 | HPGD (0.47) | KDM4EALDH1A1HPGDHSD17B10GRIA2 | |
| SCHEMBL5620076 | 0.82 | GRIA2 (0.61) | KDM4EALDH1A1HPGDHSD17B10GRIA2 | |
| SCHEMBL5621088 | 0.82 | GRIA2 (0.61) | KDM4EALDH1A1HPGDHSD17B10GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423034-B2 | Benzothiazine and benzothiadiazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-09-09 | — | — | US | disclosed |
| US-20070249594-A1 | Benzothiazine and benzothiadiazine compounds | DESOS PATRICE | 2007-10-25 | — | — | US | disclosed |
| US-7253162-B2 | Benzothiazine and benzothiadiazine compounds | LES LABORATOIRES SERVIER (FR) | 2007-08-07 | — | — | US | disclosed |
| EP-1486503-B1 | Derivatives of benzothiazine and benzothiadiazine, procedure for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2006-11-02 | — | — | EP | disclosed |
| US-20040254161-A1 | New benzothiazine and benzothiadiazine compounds | LES LABORATOIRES SERVIER (FR) | 2004-12-16 | — | — | US | disclosed |
| EP-1486503-A1 | Derivatives of benzothiazine and benzothiadiazine, procedure for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249594-A1 | Benzothiazine and benzothiadiazine compounds | GRIA4, GABRA4, GRIK4 | KDM4E 2782/4885ALDH1A1 505/4885HPGD 1165/4885 |
| US-20040254161-A1 | New benzothiazine and benzothiadiazine compounds | NR4A1, NR4A3, NR4A2 | KDM4E 1665/4885ALDH1A1 775/4885HPGD 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.